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The SARS-CoV-2 pandemic has highlighted the importance of 
viral respiratory infections as a cause of mortality and morbidity. 
Fortunately, children across the world have lower rates of COVID-19 
(disease caused by SARS-CoV-2) than adults, developing predom-
inantly asymptomatic or mild disease.[1-3] In South Africa (SA), 
<5% of COVID-19 cases have been diagnosed in children, with few 
requiring hospitalisation and even fewer requiring intensive care.[4] 
Even in children with underlying comorbidities, COVID-19 does 
not seem to be especially severe, similar to the global experience. 
Although children in low- and middle-income countries have a 
higher burden of pneumonia and severe disease from viral and 
bacterial pathogens, this pattern is not apparent with SARS-CoV-2. 
In contrast, childhood pneumonia from other pathogens remains 
the most common cause of death in children aged <5 years outside 
the neonatal period, with almost 800 000 deaths in 2018.[5,6] With 
improved socioeconomic and living conditions, strengthened 
strategies to prevent or manage paediatric HIV and immunisation 
with pneumococcal conjugate vaccine (PCV) and Haemophilus 
influenzae type b conjugate vaccine (Hib), the incidence of 
pneumonia has declined substantially, and there has been a change 
in the relative contribution of different pathogens in the pathogenesis 
of pneumonia. Nevertheless, even among HIV-negative children, 
pneumonia remains common, although the case fatality risk is 
declining. Further, pneumonia, particularly recurrent during early 
childhood, can lead to lung function impairment, setting children 
on a trajectory for the development of chronic respiratory disease 
through the life course.[7]
In SA, pneumonia accounts for ~320 000 cases and >4 000 deaths 
in children aged <5 years annually, and continues to be a major 
cause of childhood morbidity and mortality.[5] Since 2000, the 
incidence of childhood pneumonia has declined by ~50%, with 
even larger reductions in HIV-associated pneumonia.[6] Improved 
immunisation regimens, strengthening of HIV programmes with 
reductions in perinatal HIV transmission (but increasing prevalence 
of HIV-exposed uninfected (HEU) children), better socioeconomic 
conditions and new preventive strategies have contributed to the 
changes in epidemiology of childhood pneumonia. In addition, 
improved diagnostic methods and better sampling strategies 
have enabled more accurate characterisation of the pathogenesis 
and aetiology of childhood pneumonia, including the role of 
co-infections, especially in severe disease. Non-typable H. influenzae 
and Staphylococcus aureus are now the most important bacterial 
pathogens, while respiratory syncytial virus (RSV) is the major viral 
cause of childhood pneumonia.[8,9] Mycobacterium tuberculosis is 
common in the pathogenesis of acute pneumonia in SA, and its role 
is largely under-recognised.[8]
Given these changes, the SA guidelines for pneumonia in children 
aged <5 years have been revised to provide updated recommendations 
on management and prevention. Seven expert subgroups revised the 
2005 SA guideline, focusing on: (i) epidemiology; (ii) aetiology; 
(iii) diagnosis; (iv) antibiotic management and supportive therapy; 
(v) management in intensive care; (vi) prevention; and (vii) consi-
derations in children living with HIV, or HEU children. Each 
subgroup reviewed and graded the published evidence using the 
British Thoracic Society grading system. This edition of SAMJ 
contains CME articles summarising the key revisions in epidemiology 
and aetiology,[10] and diagnosis;[11] CME articles on management and 
prevention will follow.
A key issue is distinguishing children who have bacterial 
pneumonia from those with viral illness. Pneumonia comprises 
a spectrum of lower respiratory tract infection, with clinical 
features dependent on the aetiological pathogen/s, host response 
and underlying susceptibility to illness. Distinguishing bacterial 
from viral infection is difficult, especially in the context of co- 
infections.[12] It should be remembered that in young infants with cough 
and fast breathing, and wheezing or chest hyperinflation, this 
condition is commonly acute viral bronchiolitis and seldom requires 
antibiotic therapy. There is no definitive laboratory test that reliably 
distinguishes bacterial pneumonia, although C-reactive protein 
(CRP) concentrations ≥40 mg/L with radiological confirmation 
of pneumonia are suggestive of bacterial pneumonia.[13] Given 
the changes in aetiology in SA,[8,9] with expanded immunisation 
programmes, new recommendations for empirical antibiotic 
treatment of severe pneumonia now include co-amoxicillin-
clavulanate. For ambulatory illness, high-dose amoxi cillin remains 
the antibiotic of choice. 
Pneumonia deaths are largely preventable with available 
interventions. Key risk factors for pneumonia or for severe disease 
encompass child, maternal, environmental and health-system factors, 
many of which can be ameliorated. Malnutrition, prematurity, lack of 
breastfeeding, HIV infection or exposure, crowded living conditions, 
poverty, tobacco smoke or air pollution exposure are important 
determinants. Health-system factors include lack of timely access 
to effective preventive (such as immunisation) or management 
strategies. Indeed, many childhood pneumonia deaths still occur 
outside a health facility. New preventive interventions for RSV in 
young infants are promising, predominantly maternal immunisation 
in pregnancy or new long-acting monoclonal antibody formulations 
given prior to the RSV season.[14] 
While much progress has been made in SA to reduce the 
burden of childhood pneumonia, further strengthening of effective 
prevention, promotion and disease control strategies is needed 
to attain the global targets for pneumonia mortality among 
children, i.e. 3 deaths per 1 000 live births, and HiB3, diphtheria-
tetanus-pertussis (DPT3) or PCV3 uptake of 90% by 2025.[15] The 
revised SA guidelines provide updated guidance for improved 
management and prevention of childhood pneumonia, in the 
context of COVID-19 and beyond. 
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